Skip to main content
. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2

NCT01107457.

Trial name or title A Dose‐Ranging And Efficacy Study of LY2439821 (An Anti‐IL‐17 Antibody) In Patients With Moderate‐To‐Severe Psoriasis
Methods This is a randomised, placebo‐controlled, double‐blind trial.
Participants will be evaluated for treatment efficacy at multiple visits, and the primary end point will be evaluated at week 16. Participants will be followed an additional 16 to 24 weeks (32 to 40 weeks in total) after the completion of dosing in order to continue safety monitoring and to determine the duration of treatment efficacy.
Participants Inclusion criteria of the trial
  • Approximately 125 participants of either gender and over 18 years old will be randomised to 1 of 4 LY2439821 groups or to placebo (approximately 25 participants per group).

  • Plaque psoriasis covering at least 10% body surface area and a PASI score of 12

Interventions
  • LY2439821 10 mg, 25 mg, 75 mg, and 150 mg (biological)

  • Placebo (drug)

Outcomes Outcomes of the trial
  1. Change from baseline through 32 weeks in Nail Psoriasis Severity Index (NAPSI) in participants with nail psoriasis

Starting date April 2010
Contact information Eli Lilly & Co.
Study Director: phone CTLILLY (+1 877 285 4559) or phone +1 317 615 4559
Notes Status: This trial is not yet recruiting.